Cargando…
Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
KEY POINTS: Raising the mean arterial pressure (MAP) during management of hepatorenal syndrome type 1 (HRS-1) is associated with improvement in kidney function, independently of baseline MAP or model for end-stage liver disease. Raising the MAP by 15 mm Hg or greater leads to greater reduction in se...
Autores principales: | Velez, Juan Carlos Q., Karakala, Nithin, Tayebi, Kasra, Wickman, Terrance J., Mohamed, Muner M. B., Kovacic, Rosemary A., Therapondos, George, Kanduri, Swetha R., Allegretti, Andrew S., Belcher, Justin M., Regner, Kevin R., Wentowski, Cathy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Nephrology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278824/ https://www.ncbi.nlm.nih.gov/pubmed/36763632 http://dx.doi.org/10.34067/KID.0000000000000068 |
Ejemplares similares
-
Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis
por: Belcher, Justin M., et al.
Publicado: (2015) -
De Novo Immunoglobulin A Vasculitis Following Exposure to SARS-CoV-2 Immunization
por: Mohamed, Muner M. B., et al.
Publicado: (2021) -
Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome
por: Sangroongruangsri, Sermsiri, et al.
Publicado: (2021) -
The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
por: Velez, Juan Carlos Q., et al.
Publicado: (2023) -
Ultrasound Stratification of Hepatic Steatosis Using Hepatorenal Index
por: Johnson, Stephen I., et al.
Publicado: (2021)